Know Cancer

forgot password

A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients

Phase 2
21 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients

The traditional radiation treatment schedule for patients who have had a lumpectomy for
early stage breast cancer is 15 to 30 treatments delivered once a day for 3 to 6 weeks. This
treatment schedule can be inconvenient and costly for elderly, rural, uninsured, and
minority patients. This study will evaluate a new radiation treatment schedule called
whole-breast accelerated hypofractionated radiotherapy (AHF-RT). AHF-RT delivers higher
doses of radiation in fewer treatments than traditional radiation therapy. The AHF-RT
treatment course is completed with 5 radiation treatments delivered once a week for 5 weeks.

The purpose of this study is to determine if accelerated hypofractionated radiotherapy
(AHF-RT) is a safe, effective, more convenient, and less costly alternative to traditional
radiation that will offer the same chance of cure with no additional side effects.

Inclusion Criteria:

Only women who satisfy all of the following conditions will be eligible for this study.

1. must consent to be in the study and must have signed an approved consent form
conforming with federal and institutional guidelines

2. must be at least 21 years old

3. must have stage 0, I, or II breast cancer

4. On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the

5. Surgical treatment of the breast must have been breast conserving surgery (BCS). The
margins of the resected specimen must be histologically free of tumor (including DCIS
component). Reexcision of surgical margins is permitted.

6. Gross disease may be unifocal or multifocal with pathologic (invasive and/or DCIS)
tumor size excised with negative margins.

7. Patients with invasive breast cancer are required to have axillary staging which can
include sentinel node biopsy alone (if sentinel node is negative), sentinel node
biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary
nodes (if sentinel node is positive), or axillary dissection alone (with a minimum of
6 axillary nodes). Axillary staging is not required for patients with DCIS.

8. must begin adjuvant therapy (chemotherapy or radiotherapy) within 9 weeks following
the last surgery for breast cancer (lumpectomy, re-excision of margins, or axillary
staging procedure)

9. Patients must have all usual and customary hormone receptor (ER/PR) and estrogen
receptor (ER) analysis performed on the primary tumor prior to enrollment. Patients
with invasive disease must have HER2 receptor status determined (positive or
negative) with immuno-histochemistry (IHC) and/or fluorescent in-situ hybridization

10. At the time of study enrollment, patients must have had a history & physical exam
within 4 months and a bilateral mammogram within 6 months.

11. Patients with a history of non-breast malignancies are eligible if they have been
disease-free for 5 or more years prior to enrollment and are deemed by their
physician to be at low risk for recurrence. Patients with the following cancers are
eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the
cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous
cell carcinoma of the skin.

12. Patients must live in a county that is designated as Appalachian and/or rural by
Kentucky Cancer Registry Criteria (see list below) and/or must hold their primary
residence at least 10 miles from the nearest radiation facility. Patients who do not
fit these criteria may still be considered eligible if they are determined to suffer
significant financial and/or transportation hardship during a typical course of CF-RT
or HF-RT (in the judgment of any of their treating physicians). Patients who live
outside the Commonwealth of Kentucky are eligible if they fit any of these
aforementioned conditions.

- Appalachian counties in KY include: Adair, Bath, Bell, Boyd, Breathitt, Carter,
Casey, Clark, Clay, Clinton, Cumberland, Edmonson, Elliott, Estill, Fleming,
Floyd, Garrard, Green, Greenup, Harlan, Hart, Jackson, Johnson, Knott, Knox,
Laurel, Lawrence, Lee, Leslie, Letcher, Lewis, Lincoln, Madison, Magoffin,
Martin, McCreary, Menifee, Metcalfe, Monroe, Montgomery, Morgan, Nicholas,
Owsley, Perry, Pike, Powell, Pulaski, Robertson, Rockcastle, Rowan, Russell,
Wayne, Whitley, Wolfe.

Exclusion Criteria:

Men are not eligible for this study. Women with one or more of the following conditions
are ineligible for this study.

1. T3, stage III, or stage IV breast cancer

2. More than 3 histologically positive axillary nodes

3. Axillary nodes with definite evidence of microscopic or macroscopic extracapsular

4. One or more positive non-axillary sentinel node(s) (Note that intramammary nodes are
staged as axillary nodes.)

5. Palpable or radiographically suspicious ipsilateral or contralateral axillary,
supraclavicular, infraclavicular, or internal mammary nodes, unless there is
histologic confirmation that these nodes are negative for tumor

6. Suspicious microcalcifications, densities, or palpable abnormalities (in the
ipsilateral or contralateral breast) unless biopsied and found to be benign

7. Non-epithelial breast malignancies such as sarcoma or lymphoma

8. Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or
separated by 4 or more centimeters

9. Paget's disease of the nipple

10. Synchronous bilateral invasive or non-invasive breast cancer

11. History of invasive breast cancer or DCIS (Patients with a history of LCIS treated by
surgery alone are eligible.)

12. Surgical margins that cannot be microscopically assessed or are positive at
pathologic evaluation (If surgical margins are rendered free of disease by
reexcision, the patient is eligible.)

13. Treatment plan that includes regional nodal irradiation

14. Current therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or
other selective estrogen receptor modulators (SERMs), either for osteoporosis or
breast cancer prevention (Patients are eligible only if these medications are
discontinued prior to enrollment.)

15. Cosmetic breast implants (Patients who have had implants removed are eligible.)

16. Prior breast or thoracic RT for any condition

17. Collagen vascular disease, specifically dermatomyositis with a CPK level above normal
or with an active skin rash, systemic lupus erythematosis, or scleroderma

18. Pregnancy or lactation at the time of proposed randomization. Women of reproductive
potential must agree to use an effective non-hormonal method of contraception during

19. Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

ipsilateral breast tumor recurrence (IBRT), as determined by mammogram

Outcome Description:

Both invasive and non-invasive IBTRs will be considered in calculating the primary endpoint.

Outcome Time Frame:

at 5 years post completion of AHF-RT

Safety Issue:


Principal Investigator

Anthony E. Dragun, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

James Graham Brown Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

January 2011

Completion Date:

December 2020

Related Keywords:

  • Breast Cancer
  • breast cancer
  • breast neoplasm
  • breast tumor
  • radiotherapy
  • radiation
  • accelerated
  • lumpectomy
  • Breast Neoplasms



James Graham Brown Cancer CenterLouisville, Kentucky  40202